Cover Image
市場調查報告書

肝功能衰竭 : 開發平台分析

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229798
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
肝功能衰竭 : 開發平台分析 Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 86 Pages
簡介

肝功能衰竭,是指肝功能大幅度降低的狀態,由於各種肝疾病,肝臟大部分受到損傷時發生。症狀為容易發生黃疸、瘀傷和出血 、腹水、腦功能障礙、不完全的體重增加、疲勞、四肢無力感、噁心、食慾不振等。因為這些症狀與其他各種條件有關係,要正確診斷可能要花費某種程度的時間。肝功能衰竭惡化,也可能喪失方向感和產生睡意。這個階段也有昏睡和死亡的危險性。治療方法依患者肝功能的工作情形而不同。

本報告提供肝功能衰竭的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

肝功能衰竭 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

在企業開發中的治療藥

在大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Alfact Innovation
  • Cell2B S.A.
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Immune Pharmaceuticals Inc.
  • Silence Therapeutics Plc
  • Ventria Bioscience

治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALF-5755
  • Cardiotrophin-1
  • 肝功能衰竭用細胞療法
  • emricasan
  • F-573
  • GRI-0621
  • Hep-114
  • ImmuneSafe
  • 肝功能衰竭用寡核苷酸
  • 肝功能衰竭用 JNK 阻礙重組蛋白
  • 肝功能衰竭用 RNAi 寡核苷酸
  • 肝功能衰竭用 MAP 激酶4阻礙 RNAi 寡核苷酸
  • 缺血性中風、肝功能衰竭用麩胺基硫、過氧化酶活躍小分子
  • 第二型糖尿病、肝功能衰竭用 JNK 抑制劑
  • 骨關節炎、糖尿病、急性肝功能衰竭、 心肺功能甦醒後遺症、神經退化性疾病用幹細胞療法
  • VEN-100

最近的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9423IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 1, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Liver Failure (Hepatic Insufficiency) - Overview
  • Liver Failure (Hepatic Insufficiency) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
  • Alfact Innovation
  • BioLineRx Ltd
  • Cell2B Advanced Therapeutics SA
  • Conatus Pharmaceuticals Inc
  • Immune Pharmaceuticals Inc
  • Mina Therapeutics Ltd
  • Mylan NV
  • Ocera Therapeutics Inc
  • PledPharma AB
  • Promethera Biosciences SA
  • Silence Therapeutics Plc
  • Unicyte AG
  • Ventria Bioscience
  • Vital Therapies Inc
  • Liver Failure (Hepatic Insufficiency) - Drug Profiles
  • ALF-5755 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense RNAi Oligonucleotide to Inhibit FAS for Liver Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense RNAi Oligonucleotides to Inhibit MKK4 for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BL-1220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cell Therapy for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • F-573 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HepaStem - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ImmuneSafe - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MTL-CEBPA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotide for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ornithine phenylacetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • silibinin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VEN-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XEN-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Liver Failure (Hepatic Insufficiency) - Dormant Projects
  • Liver Failure (Hepatic Insufficiency) - Discontinued Products
  • Liver Failure (Hepatic Insufficiency) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
  • Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
  • Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
  • Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
  • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
  • Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
  • Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
  • Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
  • Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting
  • Apr 11, 2013: Gene inhibition helps to improve liver regeneration
  • Apr 02, 2013: ALF-5755 phase II completion
  • Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury
  • Sep 04, 2012: Ventria Bioscience And University Of Colorado Receive NIH Grant To Study Treatment Of Acetaminophen Overdose-Induced Liver Failure
  • Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure
  • May 06, 2011: ALF-5755 phase II extends to germany
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2017
  • Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top